Skip to main content
HEMOGENYX PHARMACEUTICALS PLC logo

HEMOGENYX PHARMACEUTICALS PLC — Investor Relations & Filings

Ticker · HEMO ISIN · GB00BYX3WZ24 LEI · 2138008L93GYU5GN6179 IL Manufacturing
Open in API
Filings indexed 473 across all filing types
Latest filing 2025-12-08 Major Shareholding Noti…
Country GB United Kingdom
Listing IL HEMO

About HEMOGENYX PHARMACEUTICALS PLC

https://hemogenyx.com/

Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for life-threatening diseases. The company develops treatments for blood and autoimmune diseases, as well as viral infections. Its core technology includes advanced cell-based therapies, such as its proprietary Chimeric Antigen Receptor (CAR) T-cell platform, HEMO-CAR-T, which is being developed for the potential treatment of Acute Myeloid Leukemia (AML).

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by Hemogenyx Pharmaceuticals PLC. It details an acquisition of voting rights by David John Smith, crossing a specific threshold. This is a classic regulatory disclosure regarding significant share ownership, which maps directly to the 'Major Shareholding Notification' category.
2025-12-08 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from Hemogenyx Pharmaceuticals plc regarding 'Total Voting Rights'. It specifies the total number of issued shares and voting rights, which is a standard regulatory disclosure required under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. Since this is a regulatory announcement regarding share capital and voting rights that does not fit into specific categories like 'Share Issue' (which implies a change event) or 'Major Shareholding' (which is for investors), it is best classified as a general Regulatory Filing.
2025-11-28 English
Hemogenyx Pharmaceuticals Plc - Single prospectus
Regulatory Filings Classification · 94% confidence The document is a formal 'prospectus' filed with the UK Financial Conduct Authority (FCA) for the admission of new ordinary shares to the Official List and trading on the London Stock Exchange. It contains detailed sections on risk factors, business overview, and financial information. While it relates to a share issue, it is a comprehensive regulatory prospectus document rather than a simple announcement of a share issue (SHA) or a report publication announcement (RPA). Given the specific nature of a prospectus for listing securities, it falls under the 'Regulatory Filings' category as the most appropriate fallback for this type of formal regulatory document.
2025-11-21 English
Publication of Prospectus
Capital/Financing Update Classification · 95% confidence The document is an RNS (Regulatory News Service) announcement from Hemogenyx Pharmaceuticals plc. It explicitly states the 'Publication of Prospectus' regarding the admission of new ordinary shares to the London Stock Exchange. Following the 'Menu vs Meal' rule, this is an announcement about the availability of a document (the prospectus) rather than the prospectus itself. Therefore, it is classified as a Report Publication Announcement (RPA).
2025-11-19 English
Clinical Trial Update and Grant of Share Awards
Regulatory Filings Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from Hemogenyx Pharmaceuticals regarding clinical trial progress (DSMB clearance for HG-CT-1) and a grant of Restricted Share Units (RSUs) to staff. While it mentions share grants, it is primarily a corporate update on clinical operations and regulatory milestones. Since it does not fit into specific categories like 10-K, ER, or DIRS (which is for director/insider dealing, not general staff RSU grants), and it is a standard regulatory announcement distributed via RNS, it is best classified as a general Regulatory Filing.
2025-10-29 English
Clearance to Initiate Pediatric Enrolment
Regulatory Filings Classification · 100% confidence The document is a regulatory announcement (RNS) from Hemogenyx Pharmaceuticals regarding a clinical trial update (MD Anderson clearance for pediatric enrollment). It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a general corporate announcement regarding business operations and clinical progress, it falls under the Regulatory Filings (RNS) category.
2025-10-06 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.